Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.10 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: bi-505, enlimomab pegol, alicaforsen | 0.81 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 1 stopped | 0.60 |
| literature PubMed | 59 Parkinson's papers of 23,971 | 0.46 |
| pathways Reactome | 6 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 2740
Sealed predictions
- ICAM1 in dopamine neurons, braak-0.19 (p 0.630) → +0.04 (p 0.910)receipt 2747
Swarm cases
receipt 2747: ICAM1 in dopamine neurons, braak
- power
- full sample -0.05 (p 0.840, n 18), 95% CI -0.51 to +0.43. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.03 (p 0.922, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.17 (p 0.504, n 18). could be the mix.
- skeptic
- leave-one-out range -0.18 to +0.06, sign flips 4; without severely affected donors -0.05 (p 0.840, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ICAM1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts